Dec 01 2023 This Week in Cardiology

More from AHA including SGLT2 inhibitors, blood transfusion after MI; cracks in the armor of Factor XI inhibitors; and renal denervation are the topics John Mandrola, MD, covers in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. DAPA MI Potential Dapagliflozin Benefit Post-MI Is Not a 'Mandate' https://www.medscape.com/s/viewarticle/998378 - NEJM Evidence: Dapagliflozin After MI https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300286 II. Blood Transfusion Strategy Post MI In MI With Anemia, Results May Favor Liberal Transfusion: MINT https://www.medscape.com/viewarticle/998376 - MINT NEJM -- https://www.nejm.org/doi/full/10.1056/NEJMoa2307983 - REALITY https://jamanetwork.com/journals/jama/fullarticle/2776201 - PROTECTED TAVR - https://www.nejm.org/doi/full/10.1056/NEJMoa2204961 III. FACTOR XI Impressive Bleeding Profile With Factor XI Inhibitor in AF: AZALEA https://www.medscape.com/viewarticle/998418 Asundexian Phase 3 AF Study Halted for Lack of Efficacy https://www.medscape.com/viewarticle/998665 - Abelacimab for VTE https://www.nejm.org/doi/full/10.1056/NEJMoa2105872 IV. Renal Denervation FDA Panel Split on Efficacy of Spyral Renal Denervation https://www.medscape.com/viewarticle/995800 FDA OKs Symplicity Renal Denervation System for Hypertension https://www.medscape.com/viewarticle/998664 - SPYRAL HTN OFF MED -- https://doi.org/10.1016/S0140-6736(20)30554-7 - SPRYAL HTN On Meds (Pilot Lancet 2018 ) https://doi.org/10.1016/S0140-6736(18)30951-6 - SPRYAL HTN ON Meds (Expansion Pilot) https://doi.org/10.1016/j.jacc.2023.08.045 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact [email protected]